The Motley Fool – 10 Best IPOs of 2019
InMode stock (Nasdaq: INMD) was ranked at a prestigious 3rd place on The Motley Fool’s list of 2019 best IPO. InMode stock has increased more than 200% since it’s launch just four months ago.
Investor’s Business Daily – Best Stocks of 2019
InMode (Nasdaq: INMD) was named one of the best stocks of 2019 by Investor’s Business Daily.
Yahoo! Finance Bull of the Day: INMD
Yahoo! Finance announces that InMode Ltd. (INMD) is one of the most successful IPOs of 2019, as shares soared nearly 200%. This Zacks Rank #1 (Strong Buy) is riding the social media “selfie” wave to double digit revenue growth in 2020. By 2020, medical aesthetic profits are predicted to blast through the roof to $77.6B. Famed investor Mark Cuban says medtech will produce “the world’s first trillionaires”.
InMode on UBS Investment Research Radio
UBS Investment Research Executive Director, Matt Taylor, hosted InMode on a segment of the UBS office radio station. On the panel were InMode CEO Moshe Mizrahy, CTO Michael Kreindel, and CMO Dr. Spero Theodorou. Mr. Mizrahy led the discussion, outlining InMode’s medtech innovation, from conception, to development, to commercialization. Listen to the conversation linked below to hear how InMode’s revolutionary Radio Frequency technology distinguishes it from others in the medical aesthetics industry.
Listen to the clip below.
© UBS 2019. All rights reserved. Reproduced with permission. May not be further distributed or copied.
Motely Fool Podcast – Industry Focus: Healthcare
Aesthetics surgery is a big market, and InMode is positioned to win from its growth. On November 27th, InMode was featured on the Industry Focus: Healthcare podcast, with the hosts raving about the medtech industry. Exploring this “exciting topic”, medtech stocks are “catching investors’ attention, especially with IPO market”. Medtech represents a big opportunity for investors – far bigger than the industry initially assumed, surpassing sales of $8.5B in the US over the last year, and growing at 10% annualized rate. Driven by an aging demographic and social influence, there is growing demand for the aesthetic market, and InMode stock, INMD, will continue to benefit from this trend.